688062 迈威生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-18.730-34.542-42.206-62.027-57.700
总资产报酬率 ROA (%)-9.870-23.217-30.741-47.591-47.399
投入资产回报率 ROIC (%)-10.960-25.631-33.308-52.427-56.276

边际利润分析
销售毛利率 (%)94.65798.92899.74581.02234.672
营业利润率 (%)-383.720-823.385-3,455.471-4,762.015-12,139.321
息税前利润/营业总收入 (%)-373.946-851.640-3,580.798-4,740.602-12,161.702
净利润/营业总收入 (%)-386.265-828.261-3,455.423-4,762.038-12,138.884

收益指标分析
经营活动净收益/利润总额(%)101.58899.315100.790103.896103.499
价值变动净收益/利润总额(%)0.3500.445-0.187-0.499-2.411
营业外收支净额/利润总额(%)0.2330.257-0.0010.000-0.004

偿债能力分析
流动比率 (X)1.7812.5086.2410.9053.999
速动比率 (X)1.6342.3136.0630.7573.790
资产负债率 (%)52.72842.24024.00436.7740.103
带息债务/全部投入资本 (%)44.59929.07314.78015.1833.578
股东权益/带息债务 (%)115.010228.261549.751472.5192,691.917
股东权益/负债合计 (%)90.138137.299317.053172.300873.059
利息保障倍数 (X)-35.04132.58528.561-221.160532.983

营运能力分析
应收账款周转天数 (天)50.33424.7611.3984.058287.901
存货周转天数 (天)4,849.05031,319.667303,610.3544,377.9633,309.889